Effects of simvastatin on the portal-systemic collateral vascular response to endothelin-1 and shunting degree in portal hypertensive rats

References

• Bosch J, Pizcueta P, Feu F, Fernández M, Garciá-Pagán JC. Pathophysiology of portal hypertension. Gastroenterol Clin North Am 1992;21:1–14.
   PubMed Web of Science ®Google Scholar
• Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411–15.
   PubMed Web of Science ®Google Scholar
• Pinzani M, Milani S, De Franco R, Grappone C, Caligiuri A, Gentilini A, et al. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 1996;110:534–48.
   PubMed Web of Science ®Google Scholar
• Zhang B, Calmus Y, Wen L, Sogni P, Lotersztajn S, Houssin D, et al. Endothelin-1 induces liver vasoconstriction through both ETA and ETB receptors. J Hepatol 1997;26:1104–10.
   PubMed Web of Science ®Google Scholar
• Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 1996;24:233–40.
   PubMed Web of Science ®Google Scholar
• Chan CC, Wang SS, Lee FY, Chang FY, Lin HC, Chu CJ, et al. Endothelin-1 induces vasoconstriction on portal-systemic collaterals of portal hypertensive rats. Hepatology 2001;33:816–20.
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425–30.
   PubMed Web of Science ®Google Scholar
• Hernández-Perera O, Pérez-Sala D, Navarro-Antolin J, Sánchez-Pascuala R, Hernández G, Díaz C, et al. Effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711–19.
   PubMed Web of Science ®Google Scholar
• Laufs U, La Fata V, Plutzky J, Liao J. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 1998;97:1129–35.
   PubMed Web of Science ®Google Scholar
• Laufs U, Wassmann S, Hilgers S, Ribaudo N, Böhm M, Nickenig G. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001;88:1306–7.
   PubMed Web of Science ®Google Scholar
• Omori H, Nagashima H, Tsurumi Y, Takagi A, Ishizuka N, Hagiwara N, et al. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. Br J Clin Pharmacol 2002;54:395–9.
   PubMed Web of Science ®Google Scholar
• Álvarez De Sotomayor M, Herrera MD, Marhuenda E, Andriantsitohaina R. Characterization of endothelial factors involved in the vasodilatory effect of simvastatin in aorta and mall mesenteric artery of the rat. Br J Pharmacol 2000;131:1179–87.
   PubMed Web of Science ®Google Scholar
• Huang HC, Wang SS, Lee JY, Chen YC, Lee FY, Lin HC, et al. Simvastatin effects on portal-systemic collaterals of portal hypertensive rats. J Gastroenterol Hepatol 2010;25:1401–9.
   PubMed Web of Science ®Google Scholar
• Chojkier M, Groszmann RJ. Measurement of the portal-systemic shunting in the rat by using γ-labeled microspheres. Am J Physiol 1981;240:G371–5.
   PubMed Web of Science ®Google Scholar
• Mosca P, Lee FY, Kaumann AJ, Groszmann RJ. Pharmacology of portal-systemic collaterals in portal hypertensive rats: role of the endothelium. Am J Physiol 1992;263:G544–50.
   PubMedGoogle Scholar
• Chan CC, Lee FY, Wang SS, Chang FY, Lin HC, Chu CJ, et al. Effects of vasopressin on portal-systemic collaterals in portal hypertensive rats: role of nitric oxide and prostaglandin. Hepatology 1999;30:630–5.
   PubMed Web of Science ®Google Scholar
• Hamilton RL, Berry MN, Williams MC, Severinghaus EM. A simple and inexpensive membrane “lung” for small organ perfusions. J Lipid Res 1974;15:182–6.
   PubMed Web of Science ®Google Scholar
• Lee FY, Wang SS, Tsai YT, Lin HJ, Lin HC, Chu CJ, et al. Aminoguanidine corrects hyperdynamic circulation without ameliorating portal hypertension and portal hypertensive gastropathy in anesthetized portal hypertensive rats. J Hepatol 1997;26:687–93.
   PubMed Web of Science ®Google Scholar
• Lee FY, Colombato LA, Albillos A, Groszmann RJ. Administration of N omega-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology 1993;105:1464–70.
   PubMed Web of Science ®Google Scholar
• Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007;46:242–53.
   PubMed Web of Science ®Google Scholar
• Oberti F, Pilette C, Rifflet H, Maïga MY, Moreau A, Gallois Y, et al. Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation. J Hepatol 1997;26:1363–71.
   PubMed Web of Science ®Google Scholar
• Abraldes JG, Rodríguez-Vilarrupla A, Graupera M, Zafra C, García-Calderó H, García-Pagán JC, et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl 4 cirrhotic rats. J. Hepatol 2007;46:1040–6.
   PubMed Web of Science ®Google Scholar
• Abraldes JG, Albillos A, Bañares R, Turnes J, González R, García-Pagán JC, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009;136:1651–8.
   PubMed Web of Science ®Google Scholar
• Zafra C, Abraldes JG, Turnes J, Berzigotti A, Fernández M, García-Pagán JC, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004;126:749–55.
   PubMed Web of Science ®Google Scholar
• Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide?. Lancet 1991;337:776–8.
   PubMed Web of Science ®Google Scholar
• Sitzmann JV, Li SS, Wu YP, Groszmann RJ, Bulkley GB. Decreased mesenteric vascular response to angiotensin II in portal hypertension. J Surg Res 1990;48:341–4.
   PubMed Web of Science ®Google Scholar
• Lee FY, Albillos A, Colombato LA, Groszmann RJ. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology 1992;16:1043–8.
   PubMed Web of Science ®Google Scholar
• John S, Schlaich M, Langenfeld M, Weihprecht H, Schmitz G, Weidinger G, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients. A randomized, placebo-controlled, double-blind study. Circulation 1998;98:211–16.
   PubMed Web of Science ®Google Scholar
• Bates K, Ruggeroli CE, Goldman S, Gaballa MA. Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction. Am J Physiol 2002;283:H768–75.
   Google Scholar
• Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999;33:234–41.
   PubMed Web of Science ®Google Scholar
• Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983;244:G52–7.
   PubMed Web of Science ®Google Scholar
• Sumanovski LT, Battegay E, Stumm M, Van Der Kooij M, Sieber CC. Increased angiogenesis in portal hypertensive rats: role of nitric oxide. Hepatology 1999;29:1044–9.
   PubMed Web of Science ®Google Scholar
• Sieber CC, Sumanovski LT, Stumm M, van der Kooij M, Battegay E. In vivo angiogenesis in normal and portal hypertensive rats: role of basic fibroblast growth factor and nitric oxide. J Hepatol 2001;34:644–50.
   PubMed Web of Science ®Google Scholar
• Frick M, Dulak J, Cisowski J, Jozkowicz A, Zwick R, Alber H, et al. Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells. Atherosclerosis 2003;170:229–36.
   PubMed Web of Science ®Google Scholar
• Chang CC, Wang SS, Huang HC, Lee JY, Lee FY, Lin HC, et al. Pravastatin administration does not induce detrimental effects on hemodynamics and collaterals of portal hypertensive rats. J Gastroenterol Hepatol 2010;25:1394–400.
   PubMed Web of Science ®Google Scholar
• Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol 1985;248:G618–25.
   PubMed Web of Science ®Google Scholar
• Bomzon A, Blendis LM. Animal models of liver disease. In Bomzon A, Blendis LM. editors Cardiovascular complications of liver disease. Boca Raton, FL: CRC Press; 1990. pp 9–28.
   Google Scholar